This page shows the latest Ironwood Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Consylman has more than 25 years of experience, mostly recently as CFO at Ironwood Pharmaceuticals and, before that, at Analogic Corporation and Biogen.
Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion.
Chief commercial officer Mark Mallon has taken on the CEO role at US biotech Ironwood Pharmaceuticals, while Medimmune research head Bahija Jallal agreed to take the helm of UK biotech company
The reshuffle coincides with the departure of two senior leaders: chief commercial officer Mark Mallon, who leaves to become chief executive of US biotech Ironwood Pharmaceuticals, and Bahija Jallal, who leaves
alone - perhaps modest for AZ but significant for Ironwood which made $274m in total revenues last year. ... according to Ironwood, which has said it intends to launch the drug onto the market in the fourth quarter of this year.
AZ previously sold US rights to Zurampic and the follow-up to Ironwood Pharmaceuticals for $265m plus royalties. ... The drug is approved for use alongside xanthine oxidase (XO) inhibitors such as generic allopurinol or Takeda's Uloric (febuxostat) in
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
In a "mirror deal" in April this year, AstraZenenca licensed US rights to Zurampic and the fixed dose combination to Ironwood Pharmaceuticals for $100m upfront and up to $165m in further ... collaboration, licence, equity. 73.5. PAION/ Cosmo
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel. ... Meanwhile, Valles-Sukkar arrives
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Graney most recently spent three years at Ironwood
Dr Christopher Wright joins from Axcella Health. Ironwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development officer in a role that ... Mark Currie, chief scientific officer
James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia. ... Center. Chhabra said: “Geoffrey's extensive experience leading clinical development
Ironwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors. ... Peter Hecht, CEO of Ironwood, commented on the appointment of Owens: “He has deeply probed the strategy, growth, successes and challenges of nearly every
More from appointments
Approximately 2 fully matching, plus 4 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...